Search

Your search keyword '"Pellicano, C."' showing total 181 results

Search Constraints

Start Over You searched for: Author "Pellicano, C." Remove constraint Author: "Pellicano, C."
181 results on '"Pellicano, C."'

Search Results

4. In Systemic Sclerosis Patients, Peripheral Blood CD21low B Cells and Serum IL-4 and IL-21 Influence Joint Involvement

6. POS1243 THE ROLE OF TAPSE/SPAP RATIO IN PREDICTING PULMONARY HYPERTENSION AND MORTALITY IN THE SYSTEMIC SCLEROSIS EUSTAR COHORT

8. Increased Complement Activation in Systemic Sclerosis Patients with Skin and Lung Fibrosis

9. Kidney dysfunction is associated with adverse outcomes in internal medicine COVID-19 hospitalized patients.

13. Serum and urine free light chains measurements in patients with systemic sclerosis: novel biomarkers for disease activity

14. Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson’s disease (PD_Manager): study protocol for a pilot randomised controlled trial

16. Mhealth for remote monitoring and management of Parkinson’s disease: determinants of compliance and validation of a tremor evaluation method

19. Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD-Manager): Study protocol for a pilot randomised controlled trial 11 Medical and Health Sciences 1117 Public Health and Health Services

20. Adherence to anti-Parkinson drug therapy in the 'REASON' sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the 'Morisky Medical Adherence Scale-8 items'

21. Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study

22. Clinical variables associated with treatment changes in Parkinson’s disease: results from the longitudinal phase of the REASON study

24. Cognitive impairment and its relation to imaging measures in multiple sclerosis: a study using a computerized battery

26. Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study

27. PRIAMO Study Group. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression

28. Caratteristiche Cliniche

34. Hemiparkinsonism due to frontal meningioma

35. Designing a mHealth clinical decision support system for Parkinson's disease: a theoretically grounded user needs approach.

36. Acceptability to patients, carers and clinicians of an mHealth platform for the management of Parkinson's disease (PD_Manager): study protocol for a pilot randomised controlled trial.

37. Quality and Quantity of Diffuse and Focal White Matter Disease and Cognitive Disability of Patients with Multiple Sclerosis

38. T(1) cortical hypointensities and their association with cognitive disability in multiple sclerosis

39. Relationship of cortical atrophy to fatigue in patients with multiple sclerosis

40. Serum Uric Acid/Serum Creatinine Ratio and Chronic Vascular Lesions on Renal Biopsy: A Retrospective Observational Study.

41. Clinical outcomes in patients with cardiorenal multimorbidity: the role of serum uric acid/serum creatinine ratio.

42. Effect of Secondary Infections on the Outcomes of Patients with Hematological Malignancies and SARS-CoV-2 Infection: Results from the HM-COV 3.0 Study.

43. Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio and Cardiorenal Syndrome Type 2 in the Systemic Sclerosis EUSTAR Cohort.

44. Evaluating conversion from mild cognitive impairment to Alzheimer's disease with structural MRI: a machine learning study.

45. Chest wall muscle area, ventilatory efficiency and exercise capacity in systemic sclerosis.

46. A worldwide study of subcortical shape as a marker for clinical staging in Parkinson's disease.

47. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis.

48. Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.

49. Reciprocal effects of scleroderma and temporomandibular dysfunction between patient cohorts.

50. Thymic stromal lymphopoietin and digital microvascular damage in systemic sclerosis patients: A pilot study.

Catalog

Books, media, physical & digital resources